Abstract: A current limiting device (30, 40, 50, 60) comprising for each phase of an AC supply a closed magnetic core (31) of reduced volume and mass having first and second pairs of opposing limbs (32a, 32b; 33a, 33b), and at least one AC coil (35a, 35b) enclosing opposing limbs (33a, 33b) of the magnetic core (31) and adapted for series connection with a load. A non-superconducting DC bias coil (34) typically formed of copper encloses a limb (32a, 32b) of the magnetic core (31) for saturating each of the opposing limbs (33a, 33b) in opposite directions by the bias coil (34). Under fault conditions, the AC flux in at least one limb counteracts the DC bias flux, bringing the limb out of saturation. Preferably, current is reduced in the DC bias coils thus bringing both opposing limbs of the core out of saturation.

Abstract: A system including a platform having a receptacle adapted to a bottom of a shoe or foot; securing mechanism, associated therewith; a sole for contacting a ground surface; a mechanism associated with the sole and a platform bottom, including: motor and a thrusting element, activated by the motor, the thrusting element adapted to move between the sole and the platform to apply an upward force against the platform bottom, thereby changing a platform height with respect to the sole; a sensor device adapted to associate with a lower limb, and to produce a locomotion data signal, and a microprocessor, operatively connected to the sensor device and motor, adapted to: receive locomotion information based on the signal; process the locomotion information to determine a locomotion phase, and control a timing of the mechanism, based on the determination, to change the height during a locomotion swing phase.

Abstract: The invention generally relates to thienopyridinone 5-HT4 receptor modulators, and in particular the use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with serotonin action, such as in treating Alzheimer's disease, cognition disorders, depression, and anxiety.

Abstract: Toner compositions, treated fluoropolymer particles, methods of making treated fluoropolymer particles, and the like, are disclosed.

Abstract: The invention relates to 5-HT receptor agonists and partial agonists. Novel thienopyridinone compounds represented by Formula I, and synthesis and uses thereof for treating diseases mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include Alzheimer's disease, cognition disorders, irritable bowel syndrome, nausea, emesis, vomiting, prokinesia, gastroesophageal reflux disease, nonulcer dyspepsia, depression, anxiety, urinary incontinence, migraine, arrhythmia, atrial fibrillation, ischemic stroke, gastritis, gastric emptying disorders, feeding disorders, gastrointestinal disorders, constipation, erectile dysfunction, and respiratory depression. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.

Abstract: The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.

Abstract: Ink toners, methods of making ink, and methods of changing viscosity are disclosed.

Abstract: The invention relates to 5-HT receptor antagonists. Novel piperidinylamino-thieno [2,3-d] pyrimidine compounds represented by Formula I, and synthesis and uses thereof for treating diseases mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include central nervous system disorders such as pulmonary arterial hypertension, migraine, hypertension, disorders of the gastrointestinal tract, restenosis, asthma, obstructive airway disease, prostatic hyperplasia and priapism, anxiety, depression, schizophrenia, neural injury and stroke. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also provided.

Abstract: The invention is a dosing pump that can be worn on the body of a patient for subcutaneously delivering liquid with centi-micro liter accuracy to his/her body. The dosing pump comprises a pump unit, an internal control unit; and a reservoir containing the liquid. The pump unit comprises a pump block (12) comprising a pump chamber (118) with a pump diaphragm (107) stretched across its entrance and a pump pin cylinder (110) extending from the exterior of the pump block to the entrance to the pump chamber; a pump pin (20) that is located in the pump pin cylinder and a motor unit comprising a motor and gear system. When the motor is activated, the rotational motion of the motor and the gears in the gear system is transformed into cyclic back and forth linear motion of the pump pin in the pin cylinder pumping the liquid from the reservoir into the patient.

Abstract: The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.

Abstract: The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.

Abstract: The invention relates to 5-HT receptor modulators, particularly 5-HT2B antagonists. Novel piperidinylamino-thieno[2,3-d]pyrimidine compounds represented by Formula I, II and III, and uses thereof for treating conditions including pulmonary arterial hypertension, congestive heart failure, and hypertension.

Abstract: The invention relates to 5-HT receptor modulators, particularly 5-HT2B antagonists. Novel piperidinylamino-thieno[2,3-d]pyrimidine compounds represented by Formula I, II and III, and uses thereof for treating conditions including pulmonary arterial hypertension, congestive heart failure, and hypertension.

Abstract: The invention generally relates to thienopyridinone 5-HT4 receptor modulators, and in particular the use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with serotonin action, such as in treating Alzheimer's disease, cognition disorders, depression, and anxiety.

Abstract: A system including: (A) a device including: (a) a platform having, on a top side, a receptacle adapted to receive at least a portion of a bottom of a shoe or foot of the user; (b) a securing mechanism, associated with the receptacle; (c) at least one sole adapted to contact a ground surface; (d) a mechanism, at least partially disposed between, and operatively associated with, the sole and a bottom side of the platform, including: (i) a motor, for operatively connecting to a power source, and (ii) at least one thrusting element, mechanically associated with, and activated by, the motor, the thrusting element adapted to move, when in thrusting mode, between the sole and the platform so as to apply an upward force against the bottom side of the platform, thereby changing a height of at least a portion of the platform with respect to the sole; (B) a sensor device including a sensor adapted to associate with a lower limb of the user, and to produce a data signal related to locomotion of the user, and (C) a microp

Abstract: The invention relates to 5-HT receptor agonists and partial agonists. Novel thienopyridinone compounds represented by Formula I, and synthesis and uses thereof for treating diseases mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include Alzheimer's disease, cognition disorders, irritable bowel syndrome, nausea, emesis, vomiting, prokinesia, gastroesophageal reflux disease, nonulcer dyspepsia, depression, anxiety, urinary incontinence, migraine, arrhythmia, atrial fibrillation, ischemic stroke, gastritis, gastric emptying disorders, feeding disorders, gastrointestinal disorders, constipation, erectile dysfunction, and respiratory depression. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.

Abstract: The invention relates to 5-HT receptor agonists and partial agonists. Novel thienopyridinone compounds represented by Formula I, and synthesis and uses thereof for treating diseases mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include Alzheimer's disease, cognition disorders, irritable bowel syndrome, nausea, emesis, vomiting, prokinesia, gastroesophageal reflux disease, nonulcer dyspepsia, depression, anxiety, urinary incontinence, migraine, arrhythmia, atrial fibrillation, ischemic stroke, gastritis, gastric emptying disorders, feeding disorders, gastrointestinal disorders, constipation, erectile dysfunction, and respiratory depression. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.

Abstract: It is provided a system for improving locomotion of a human user, by changing an inclination or height of a stance surface of a device for donning on a leg during walking. The system includes a device, a sensor and a microprocessor. The device includes a platform which securely receives the shoe or foot of the user, a sole and mechanisms between the platform and the sole. Each mechanism has a motor and a thrusting element which changes the height of the platform relative to the sole. The sensor is associated with the lower limb, it senses the locomotion of the user and issues a corresponding data signal to the microprocessor. The microprocessor processes the locomotion information, determines the locomotion phase, and controls the mechanisms to effect changing of the inclination and/or the height of the stance surface during a swing phase. Also, the microprocessor introduces random changes thereof.

Abstract: The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules.

Abstract: The invention relates to 5-HT receptor agonists or antagonists. Novel arylpiperazinyl sulfonamide compounds represented by Formula I, and synthesis and uses thereof for treating diseases including those mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include central nervous system disorders such as generalized anxiety disorder, ADD/ADHD, neural injury, stroke, and migraine. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.